Scientists of the University of Helsinki have developed a molecule that can inactivate the SARS-COV-2 coronavirus S-protein and ensure effective short-term protection against infection. This is reported by News Medical Edition. The preliminary results of the study have not yet been reviewed by other specialists.
The Trisb92 connection protects against coronavirus for at least eight hours after the intended contact with infected, and it remains effective even with a high risk of infection. The action of the molecule begins immediately after the nasal introduction to the body, which distinguishes it from the vaccine. It is aimed at a spike protein area that binds to the human cell receptor and ensures the penetration of the virus inside the cell.
Specialists have shown that Trisb92 is able to prevent even the development of atypical pneumonia when infected by the SARS-COV virus, the outbreak of which occurred in the early 2000s. This indicates the possibility that the molecule can protect not only from COVID-19, but also from other dangerous potential infections, whose pathogens will be new coronaviruses. It is expected to be clinical trials of the drug, which is a probable supplement for vaccines, will begin in the spring.